荣昌生物
(688331)
| 流通市值：89.96亿 | | | 总市值：302.38亿 |
| 流通股本：1.62亿 | | | 总股本：5.44亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 622,789,439.47 | 743,392,716.82 | 609,013,239.33 | 1,263,778,895.77 |
| 应收票据及应收账款 | 407,083,914.32 | 376,373,283.88 | 274,218,052.26 | 152,962,458.25 |
| 其中：应收票据 | 110,706,722.42 | 78,695,674.95 | - | - |
| 应收账款 | 296,377,191.9 | 297,677,608.93 | 274,218,052.26 | 152,962,458.25 |
| 应收款项融资 | 61,693,042.71 | 44,044,931.02 | 138,850,954.06 | 81,331,633.37 |
| 预付款项 | 291,290,257.15 | 270,294,849.12 | 263,521,938.71 | 259,632,042.31 |
| 其他应收款合计 | 49,435,238.53 | 29,011,543.89 | 28,663,216.01 | 24,422,325.27 |
| 存货 | 751,473,242.66 | 741,559,576.19 | 716,315,388.4 | 708,468,106.97 |
| 其他流动资产 | 18,403,477.85 | 24,255,054.24 | 22,734,934.63 | 8,313,340.01 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,202,168,612.69 | 2,228,931,955.16 | 2,235,196,172.88 | 2,760,019,446.23 |
| 非流动资产: | | | | |
| 长期股权投资 | 9,000,788.49 | 2,705,448.2 | 2,705,351.67 | 2,706,281.98 |
| 其他权益工具投资 | 68,486,996.52 | 93,521,672.55 | 137,060,675.39 | 81,304,390.64 |
| 其他非流动金融资产 | 1,950,535.39 | 2,000,000 | - | - |
| 固定资产 | 2,195,752,559.07 | 2,031,305,563.72 | 1,900,710,314.44 | 1,689,716,104.81 |
| 在建工程 | 623,143,112.34 | 795,718,495.54 | 874,410,600.56 | 892,286,169.28 |
| 使用权资产 | 123,292,317.05 | 132,248,412.02 | 144,682,175.35 | 160,232,091.93 |
| 无形资产 | 144,875,167.66 | 143,781,479.65 | 59,112,635.88 | 60,163,434.22 |
| 长期待摊费用 | 6,701,387.06 | 6,833,576.52 | 6,836,434.04 | 7,447,366.89 |
| 递延所得税资产 | - | - | 3,662,653.49 | 1,218,104.42 |
| 其他非流动资产 | 103,285,416.55 | 91,194,101.23 | 149,980,324.92 | 176,019,942.05 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,276,488,280.13 | 3,299,308,749.43 | 3,279,161,165.74 | 3,071,093,886.22 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,478,656,892.82 | 5,528,240,704.59 | 5,514,357,338.62 | 5,831,113,332.45 |
| 流动负债: | | | | |
| 短期借款 | 574,000,648.97 | 284,276,638.87 | 14,378,016 | 11,849,497.74 |
| 应付票据及应付账款 | 125,408,470.48 | 139,330,943.32 | 173,656,953.25 | 262,041,715.17 |
| 其中：应付票据 | - | 13,994,347.44 | 59,244,656.92 | 139,406,668.17 |
| 应付账款 | 125,408,470.48 | 125,336,595.88 | 114,412,296.33 | 122,635,047 |
| 合同负债 | 9,833,198.56 | 11,398,410.09 | 192,216.18 | 1,323,787.07 |
| 应付职工薪酬 | 180,021,573.9 | 194,940,951.34 | 180,556,528.8 | 158,297,635.52 |
| 应交税费 | 10,605,606.48 | 34,694,547.74 | 25,719,247.85 | 7,281,259.94 |
| 其他应付款合计 | 310,520,251.58 | 391,160,258.67 | 329,478,051.75 | 344,609,614.49 |
| 一年内到期的非流动负债 | 59,283,276 | 60,443,433.9 | 59,466,801.09 | 61,866,763.95 |
| 其他流动负债 | 12,929,940.25 | 11,877,366.49 | 11,360,693.52 | 7,686,915.38 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,282,602,966.22 | 1,128,122,550.42 | 794,808,508.44 | 854,957,189.26 |
| 非流动负债: | | | | |
| 长期借款 | 1,003,365,763.39 | 840,588,019.63 | 628,164,507.05 | 530,929,063.74 |
| 租赁负债 | 64,398,237.87 | 74,675,060.11 | 84,989,284.41 | 96,925,225.44 |
| 递延收益 | 49,737,729.6 | 46,075,693.04 | 50,153,561.13 | 53,150,138.4 |
| 递延所得税负债 | - | 1,511,227.5 | - | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,117,501,730.86 | 962,850,000.28 | 763,307,352.59 | 681,004,427.58 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 2,400,104,697.08 | 2,090,972,550.7 | 1,558,115,861.03 | 1,535,961,616.84 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 544,332,083 | 544,263,003 | 544,263,003 | 544,263,003 |
| 资本公积 | 6,251,640,596.24 | 6,237,868,188.53 | 6,208,194,353.94 | 6,191,076,299.34 |
| 减:库存股 | 440,663,441.59 | 440,310,281.32 | 423,315,645.36 | 396,758,204.1 |
| 其他综合收益 | -74,324,957.4 | -51,042,368.3 | -33,163.06 | 2,212,625.88 |
| 未分配利润 | -3,202,432,084.51 | -2,853,510,388.02 | -2,372,867,070.93 | -2,045,642,008.51 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,078,552,195.74 | 3,437,268,153.89 | 3,956,241,477.59 | 4,295,151,715.61 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,078,552,195.74 | 3,437,268,153.89 | 3,956,241,477.59 | 4,295,151,715.61 |
| 负债和股东权益合计 | 5,478,656,892.82 | 5,528,240,704.59 | 5,514,357,338.62 | 5,831,113,332.45 |
| 公告日期 | 2024-04-27 | 2024-03-28 | 2023-10-31 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |